Last reviewed · How we verify
Provera (medroxyprogesterone)
Medroxyprogesterone is a synthetic progestin that binds to progesterone receptors to suppress ovulation and alter the endometrium.
Medroxyprogesterone is a synthetic progestin that binds to progesterone receptors to suppress ovulation and alter the endometrium. Used for Contraception, Abnormal uterine bleeding, Endometriosis.
At a glance
| Generic name | Provera (medroxyprogesterone) |
|---|---|
| Also known as | Provera |
| Sponsor | University Hospital of North Norway |
| Drug class | Progestin |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Gynecology/Contraception |
| Phase | FDA-approved |
Mechanism of action
Medroxyprogesterone acts as a progestin by binding to progesterone receptors in the hypothalamus, pituitary, and reproductive tissues. It inhibits the luteinizing hormone (LH) surge needed for ovulation and thickens cervical mucus to prevent sperm penetration. It also alters the endometrial lining to prevent implantation, making it effective for contraception and hormone replacement therapy.
Approved indications
- Contraception
- Abnormal uterine bleeding
- Endometriosis
- Hormone replacement therapy
Common side effects
- Irregular bleeding or amenorrhea
- Weight gain
- Headache
- Breast tenderness
- Mood changes
- Injection site reactions (if IM formulation)
Key clinical trials
- SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer
- Doxycycline and Progestin Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive Failure(RRF) (NA)
- Effect of Twin Hearts Meditation and Mandala Coloring on Exam Anxiety in Nursing Students (NA)
- Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification (PHASE2, PHASE3)
- Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months (PHASE3)
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (PHASE2)
- Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease (PHASE4)
- Intrauterine Stent Placement Following Hysteroscopic Septum Resection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |